Patients with mild COVID-19 still produce antibodies to SARS-COV-2: MedRxiv, Institut Pasteur, France

Coronavirus by Engin Akyurt via pixabay.com (open access)

A study from the Institut Pasteur in Paris was published on the preprint server MedRxiv on May 19 (full text .pdf file here).  In this study, healthcare workers were recruited to assess antibodies to SARS-COV-2 (the spike protein) after they had recovered from mild COVID-19 confirmed by RT-PCR tests (nasopharyngeal swabs).  None of the patients required hospitalization during their illnesses.  Their median age was 32, and most were medical students, doctors, or nurses.  Of the 160 participants, 74 had known contact with virus patients at work and 38 met virus-infected people away from a “health care setting”.  The rest apparently had unknown contacts and may have been infected by asymptomatic carriers.

One hundred and fifty five (96.9%) had symptoms consistent with COVID-19 (dry cough, fever, dyspnea, anosmia or ageusia). The median time between onset of symptoms and PCR testing was 2 days (IQR:1-4), and the median time from onset of symptoms to blood sampling was 24 days (IQR: 21-28, range 13-39).

159 of the 160 participants had detectable antibodies to SARS-COV-2 spike protein, with higher levels noted later after the illness (the earliest sample was taken 13 days after onset.) The only participant who had no detectable antibodies was a 58 y/o man who had persistent symptoms 18 days after onset of illness, when blood was drawn for the test.  91% of the participants also had neutralizing antibodies to the virus, with a maximum of 97% after 28 days.  In the discussion, the authors relate that other studies showed higher antibody titers with more severe disease; in this study, virtually all patients with mild disease developed antibodies.

This study demonstrates that patients who recover from mild COVID-19 will develop antibodies, most of them demonstrating neutralizing ability against the virus.  In animal studies, neutralizing antibodies have shown immunity against re-infection; thus, even mild disease should confer protection.  Additional findings:

Interestingly, in our study, individuals with factors associated with more severe disease (e.g., male sex, high body mass index and high blood pressure), were more likely to have high titers of neutralizing antibodies compared to others. This may be due to a higher antigenic burden in such individuals, which will generate a stronger humoral response, or may, on the contrary, suggest that some antibodies may play a deleterious role during infection [15]. Future studies are warranted to characterize the beneficial or detrimental role of specific antibodies in COVID-19 patients and the minimal titer required for protection.

This study was publicized in a story in the Guardian on May 27.  The story states that the study was prompted by multiple illnesses reported after an evangelical retreat in Mulhouse, France in early March– what they described as a “super-spreader” event.  The study was said to be focused on the 80% of people infected who develop mild disease.  Earlier studies were conducted on patients after hospitalization for severe illness.  “Early reports had suggested an absence or limited presence of antibodies in some individuals with mild symptoms.”

This contributes to our understanding that COVID-19 illness results in immunity for the vast majority of those affected, even with mild disease.  Previous reports had questioned the development of antibodies in patients who were not severely ill.  Based on prior experience with SARS-COV-1, immunity is expected to last at least two years.